Riferimento:
Intern Med. 2010;49(15):1557-63.
Autori:
Yamaguchi M1, Yamada Y, Hosokawa Y, Iwamoto R, Tamba S, Ihara A, Yamamoto K, Hoshida Y, Matsuzawa Y.
Fonte:
Intern Med. 2010;49(15):1557-63.
Anno:
2010
Azione:
Octreotide sopprimere la secrezione di gastrina nei pazienti con gastrinoma metastatico.
Target:
Octreotide/gastrinoma metastatico.
ABSTRACT
A 30-year-old woman had a history of prolactinoma and primary hyperparathyroidism. She was diagnosed as having multiple endocrine neoplasia type 1 with gastrinoma and liver metastases. Octreotide therapy was started and the serum gastrin level decreased immediately. Octreotide continued to suppress gastrin secretion over the next 7 years. The Ki67/MIB1 proliferation index of this tumor was only 0.5 % and somatostatin receptor (SSTR) 2 expression was very strong in both 2002 and 2009. This case suggests the importance of investigating the Ki67/MIB1 index and SSTR expression in patients with metastatic gastrinoma.
Free full text
Sostanze: